Introduction
Charcot-Marie-Tooth (CMT) diseases or hereditary motor and sensory neuropathies are the most common inherited disorders of the peripheral nervous system (PNS) with a prevalence of up to one in 2500. 1, 2 Affected humans develop a slowly progressive, distally pronounced muscle atrophy along with weakness, subsequent walking disabilities and sensory impairments. The CMT disease onset and progression are strikingly variable and a therapy is not available. 3 -6 In the 1960s, prior to genetic insight, the first classification of seven CMT subtypes was introduced, demonstrating the wide clinical heterogeneity of the disease. 7 Today, this classification even provides the basis for the clinical categorization of CMT, and the electrophysiological value of the motor nerve conduction velocity (NCV) is used to distinguish the demyelinating CMT type 1 (CMT1) with strongly reduced NCV (,38 m/s) from the axonal CMT type 2 (CMT2) with normal or slightly reduced NCV. 8, 9 From the 1990s on, rapid progress in genetics led to the identification of a large number of genomic loci associated with CMT. Importantly, different genetic defects in various genes result in a very similar clinical phenotype, and disease genes alone are not sufficient to meet the requirements of a practical CMT categorization. Therefore, the currently applied classification system incorporates both genetic and clinical characteristics.
Approximately 15 years ago, the first genetically modified animal models with a CMT-like pathology and clinical phenotype were generated. 10 -13 Only naturally occurring mouse mutants such as the Trembler mice were available previously. 14 Numerous CMT rodent models have been created since then and the knowledge about the nature of CMT disease has greatly expanded in the last 10 years, as discussed in recent reviews and at the 183rd European Neuromuscular Center workshop in 2011. 9,15 -19 Importantly, several recent human therapeutic trials with ascorbic acid (Vitamin C) have failed despite the promising data derived from a CMT mouse model, leaving the urgent need for treatment unresolved. 20 -23 Here, we will briefly introduce the clinically relevant murine models and critically discuss their capability for preclinical therapeutic approaches. Low copy number Pmp22 transgenic animal models best phenocopy CMT1A patients
The underlying genetic defect for the most prevalent CMT1A, clinically characterized by demyelination and reduced NCV, is an intrachromosomal duplication on chromosome 17p11.2. 24, 25 The gene for the peripheral myelin protein 22 kDa (PMP22) is located within the duplicated region and its increased gene dosage is causative for the disease. 12, 26, 27 PMP22 is a small hydrophobic transmembrane protein, which is, next to ubiquitous expression, located in the compact myelin of Schwann cells in the PNS. 28 Patients with CMT1A exhibit 1.7-fold PMP22 mRNA overexpression in Schwann cells, 29 although this is not a consistent finding. 30 Demyelination, concentric layers of multiple promyelinating Schwann cells around naked axons (onion bulbs) and secondary axonal loss are typical histopathological features of peripheral nerves in patients with CMT1A. 9 Several Pmp22 transgenic mouse lines 11, 13, 31, 32 and one line of Pmp22 transgenic rats (CMT rat) 12 have been generated by the integration of extra copies of the cloned Pmp22 gene ( Table 1 ). The CMT rat was generated by pronuclear injection of a cosmid-derived 43-kb DNA fragment, habouring the entire murine Pmp22 gene. 12 CMT rats carry approximately three copies (hence 'low copy') of the wild-type mouse Pmp22 gene, resulting in an 1.6-fold mRNA overexpression in peripheral nerves when quantified by quantitative polymerase chain reaction.
12, 33 Young CMT rats display mild dysmyelination, but no alteration of axon number and diameter. 34, 35 In contrast, older CMT rats show a hypomyelination, onion-bulb formation, reduction in the mean axon size as well as axonal loss. Moreover, Pmp22 transgenic rats suffer from progressive muscle atrophy resulting in a grip strength reduction and an impaired gait. 33, 36 Although CMT rats were derived from one founder and hence harbour the same transgenic modification, they recapitulate a striking disease variability after being kept on an outbred background for numerous generations. 35 A high disease variability has been reported from humans affected by CMT1A within the same family and even among monozygotic twins. 37, 38 Hence, the CMT rat models important molecular, histological and phenotypical hallmarks of patients with CMT1A particular well, rendering it an adequate animal model for testing the therapeutic compounds. When bred to homozygosity, Pmp22 transgenic rat displays a severe amyelinating phenotype, resulting in limb paralysis and adolescent death, 12, 39 resembling congenital hypomyelinating neuropathy (CHN) and Déjerine Sò ttas syndrome (DSS) in patients. Next to the CMT rat, various transgenic mouse models have been generated, many of which carry a high number of additional genomic Pmp22 copies ( Table 1 ). The TgN248 line was transgenically engineered using the identical Pmp22 mouse cosmid applied for the generation of the CMT rat. TgN248 mice harbour 16 transgene copies and overexpress Pmp22 mRNA 2-fold. 13 In addition, the C22 heterozygous (het) line was generated by overexpressing the human PMP22 gene which was cloned into a yeast artificial chromosome (YAC). This line carries seven to eight additional copies of the PMP22 gene and animals display a 2.7-fold PMP22 mRNA overexpression. 11, 40 Both lines, C22 het and TgN248, as well as the My41 line, a mouse Pmp22 YAC transgenic model, 32 display severe developmental histological and behavioural phenotypes with reduced life span and may resemble mouse models for severe forms of CMT1A, CHN and DSS. However, a reduced life span is not a feature of CMT patients which must be kept in mind, when selecting these animal models for preclincal trials. In contrast, a further human PMP22 YAC transgenic mouse line (C61 het line) holds approximately four transgene copies and shows a mild phenotype upon 2-fold PMP22 mRNA overexpression. 31 More recently, a new mouse line (C3) with moderate PMP22 overexpression has emerged from the C22 het progeny after losing approximately half of the transgene copies. 41 Histologically, mice of the C61 het and the C3 lines develop normal myelin and show consecutive demyelination and axonal loss (R. Stassart and R. Fledrich, unpublished). 31, 41 Next to the CMT rat, these two lines may thus be the most appropriate mouse models for CMT1A.
Hereditary neuropathy with liability to pressure palsies can be modelled in Pmp22 hemizygous mutants
In CMT1A, the duplication of one PMP22 allele is commonly due to an unequal crossing over in meiosis during spermatogenesis. 26 The genetic counterpart, a deletion of one PMP22 allele, causes hereditary neuropathy with liability to pressure palsies (HNPP). 42 Clinically, patients with HNPP display episodic palsies and paresthesias following minor nerve trauma or pressure exposure to peripheral nerves.
However, many patients remain undiagnosed as clinical symptoms remain mild. 43 The pathological hallmark of HNPP is the presence of focal myelin outfoldings (tomacula), observed in histological sections of peripheral nerve. 44 A mouse model hemizygous for the Pmp22 gene has been generated which display tomacula formation and late onset demyelination, similar to patients with HNPP. 45, 46 Similar to mildly affected patients, these mice lack an obvious clinical phenotype. However, electrophysiological analysis after an experimental nerve compression results in conduction blocks in Pmp22 hemizygous mice.
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CMT1E is modelled by naturally occuring mouse mutants carrying point mutations in the Pmp22 gene
In humans, PMP22 point mutations account for only 2.5% of all CMT cases and mostly underlie the severe forms of demyelinating peripheral neuropathies, CHN and DSS. 48 Neuropathies caused by PMP22 point mutations were historically referred to as CMT1A but are now termed CMT1 type E. 4 Interestingly, a family with a rare axonal CMT form (CMT2) was recently described carrying a dominant point mutation in the PMP22 gene. 49 The spontaneous, dominantly inherited mutations in the Pmp22 gene result in leucine-to-proline (L16P) or glycine-to aspartic acid (G160D) replacements in the PMP22 protein of the Trembler-J (Tr J) or Trembler (Tr) mouse, respectively (Table 1) . 14, 50, 51 An identical Tr J single-point mutation in a severely affected CMT disease type 1E (CMT1E) family 52 allows the use of these mice as models for the corresponding human disease. Heterozygous Tr J mice display a normal life span and develop only a mild late onset demyelinating neuropathy. 53 In contrast, homozygous Tr J mice exhibit severe developmental defects, fail to establish proper myelin and usually die around postnatal day 16. 53 In contrast to homozygous Tr J/Tr J, the life span of Tr/Tr mice is not reduced although peripheral myelin is also virtually absent. 54 Interestingly, in mice heterozygous for the Tr allele, the progression of the disease is more rapid than in heterozygous Tr J mice, leading to prominent histological abnormalities (e.g., 'onion bulb' formation) in aged animals. 53 The pathomechanism leading to myelination defects in these mutants remains poorly understood. However, for both strains, Tr and Tr J, altered PMP22 protein folding, trafficking and accumulation in Schwann cells were described, and the differences in the phenotype may be due to different susceptibilities to form protein aggregates containing mutant PMP22 as described below.
Animal models of myelin protein zero-related neuropathies resemble patients with CMT1B
MPZ or P0 is an immunoglobulin-related adhesion molecule and constitutes the most abundant myelin protein in peripheral nerve. 60, 61 More than 100 different mutations in the MPZ gene have been identified in patients suffering from autosomal demyelinating hereditary neuropathies, and engineered animal models are available for some of them (Table 1) . 62 Interestingly, there is a growing number of MPZ mutations which lead to axonal CMT. 63 -68 Mild forms are termed CMT type 1B, the third most common CMT form, whereas severe forms are referred to as CHN and DSS. 62, 63 Recently, two families with MPZ duplication and peripheral neuropathy have been reported. 69, 70 Cases with a deletion of an entire MPZ allele are so far not known. In mice, a heterozygous null allele causes a relatively mild demyelinating phenotype and mice are indistinguishable from wild-type littermates until postnatal week 4. 10 Mouse models which completely lack functional Mpz genes exhibit a progressive behavioural phenotype and fail to establish compact myelin in a large proportion of nerve fibres. 10 Years before, the recent reports of MPZ duplication cases in humans has already been shown that transgenic overexpression of the MPZ gene is not tolerated and causes a severe CHN-like phenotype in mice. 71 However, MPZ mutations associated with severe forms of inherited neuropathy result in transcripts harbouring premature stop codons within terminal exons that are not subject to the non-sense-mediated decay (NMD) surveillance system. 72 Therefore, erroneous mRNA is not degraded but translated into truncated proteins with potential dominant-negative activity and subsequent aggregation in the endoplasmatic reticulum (ER). 72 Protein products of other MPZ mutations which also escape the NMD but are not retained in the ER can be integrated into the myelin sheath. A resulting mild CMT-associated phenotype may likely be the consequence of the loss of function mutations in one MPZ gene that can be partially rescued by the intact allele, as underlined by the mild phenotype in heterozygous Mpz null mice (see above). 10, 73 In humans, the deletion of Mpz serine 63 (S63del) or its mutation to Mpz cysteine 63 (S63C) exert demyelinating mild late onset CMT type 1B and severe early onset DSS, respectively. 74, 75 The respective pathological mechanisms are apparently different; MpzS83del is retained in the ER, whereas MpzS63C is misarranged into the myelin sheath. 76 Genetically, engineered mice harbouring mutated MpzS63del come closest to human CMT1B, exhibiting distally pronounced demyelination, reduced NCV and signs of muscle atrophy. 76 
Mouse models of rare demyelinating CMT disease subtypes
Mouse mutants carrying mutations in the Gjb1 gene resemble patients with CMT1X
The GJB1, historically termed connexin-32 (Cx32), is located in the noncompact myelin of the PNS and CNS and mutations cause the second most common demyelinating CMT (CMT1X). 27 CNS signs and symptoms have been found in some patients with CMT1X. 77 More than 250 disease-causing mutations have been described and the X-linked inheritance explains the fact that male patients are clinically affected and females show only subclinical signs, e.g. NCV slowing. 78 Despite the high number of reported mutations in the GJB1 gene causing CMT1X in humans, the resulting clinical severity appears to be relatively uniform, including those with a deleted gene. Hence, most mutants are thought to cause a loss of function. 79, 80 Mice hemizygous for the Gjb1 gene may therefore be practical to study human CMT1X. 81 Mice lacking both Gjb1 alleles as much as mice transgenically expressing mutant Gjb1 (R142W) phenocopy human CMT1X patients and develop a late onset demyelinating neuropathy predominantly affecting motor fibres (Table 1) . 78,82 -85 Transgenic expression of Gjb1 under the control of the Schwann-cell-specific Mpz promoter rescued the phenotype in mice which lack endogeneous Gjb1, indicating that the loss of Schwann-cell-autonomous expression of Gjb1 causes demyelination in CMT1X. 86 Interestingly, in Gjb1-deficient mice, the numbers of T-lymphocytes and macrophages are upregulated in peripheral nerve tissue.
87,88
Periaxin Periaxin (PRX) is a cytoskeletal component of Schwann cells and is located in the non-compact myelin. 89 PRX is required for the formation of cytoplasmic compartments in the Schwann cell, the bands of Cajal, which are important for proper elongation during development, possibly determining the internodal length. 90 Mutations in the PRX gene have been reported to cause a severe early-onset autosomalrecessive demyelinating neuropathy, referred to as CMT4F. 91 PRX-deficient mice develop focal myelin outfoldings (tomacula), infoldings and progressive demyelination, display the lack of cajal bands and show a decreased internodal length. 90, 92 Interestingly, these mice also develop a broad sensory phenotype including thermal hyperalgesia and mechanical allodynia, 92 making them an interesting tool to study CMT4F and neuropathic pain.
Early growth response 2
The transcription factor early growth response 2 (EGR2; historically termed KROX-20) is a key regulator of differentiation and myelin gene expression in Schwann cells. 93 Mutations in the gene encoding EGR2 result in variable phenotypes ranging from demyelinating CMT type 1D (CMT1D) to CHN. 94, 95 Egr2-deficient mice die shortly after birth and display severe peripheral dysmyelination, whereas Schwann-cell differentiation is arrested in a premyelinating state. 93 On the contrary, hemizygous mice which have only one copy of the Egr2 gene show neither abnormal myelination nor reduced life span, 93 suggesting that mutations in the EGR2 gene may cause dominant negative effects rather than loss of functions in human CMT1D.
Myotubularin-related protein 2/13 (MTMR2, MTMR13) and FIG4
Mutations in the myotubularin-related protein 2 (MTMR2) gene have been reported to cause a rare early-onset autosomal-recessive demyelinating neuropathy, referred to as CMT type 4B1 (CMT4B1). 96, 97 MTMR2 is a member of the phosphoinositide-3-phosphatase which dephosphorylates phosphatidylinositol-3,5-bisphosphate (PIP 2 ), an important second messenger which is crucial for myelin biogenesis and homeostasis and implicated in membrane trafficking. 98, 99 Mice with truncated MTMR2 show distally pronounced myelin outfoldings, very similar to CMT4B1 patients. 100, 101 Interestingly, MTMR2 can interact with a related but enzymatically inactive phosphatase (MTMR13) 102 and mutations in the MTMR13 gene underlie the clinically very similar neuropathy CMT4B2. 103, 104 The loss of FIG4, a 5-phosphatase of PIP 2 , in humans causes CMT type 4J, another recessive demyelinating neuropathy. 105 Mice lacking FIG4 provoke the plt ( pale tremor) phenotype accompanied with massive neurodegeneration and peripheral neuropathy. 105, 106 Both, erroneous MTMR2 and FIG4, demonstrate the importance of PIP 2 homeostasis for myelination. 107 
Therapeutic strategies in CMT1A
So far, the majority of preclinical trials have been conducted in animal models of demyelinating forms of CMT (CMT1). In the following, we will, therefore, focus on the most frequent subtype of CMT disease caused by PMP22 overexpression (CMT1A). The hallmark of CMT is axonal loss that causes muscle atrophy and the clinical symptoms (Fig. 1) . The molecular mechanisms of the axonal loss, the 'common final pathway', is not known, but is under intense investigation by a number of laboratories. 19 However, in the case of CMT1A, some pathophysiological processes that lead to the axonal loss are evident and offer targets for therapeutic interventions (Fig. 1) .
Progesterone antagonist lowers Pmp22 overexpression and ameliorates the clinical phenotype of CMT rats
One obvious therapeutic strategy in CMT1A is lowering the toxic overexpression of the PMP22 gene. This notion was derived from Pmp22 transgenic rats which show high variability in the levels of Pmp22 mRNA expression and the severity of the clinical phenotype. 12, 108 However, it is important to note that the expression of PMP22 is strongly manipulated by several cis-acting non-coding genomic regions such as distal upstream and intronic enhancers. 109, 110 These findings are supported by the fact that humans with a duplication of only the upstream region of PMP22, excluding the disease gene itself, resemble a mild CMT-like phenotype. 111 In the reported rodent models, the PMP22 transgenes (cosmids and YACs, see above and Table 1 ) contain either the entire human or murine genomic region, including intronic sequences and short upstream fragments, but lack distal upstream regulatory units. The absence of specific elements in these models may hamper the identification of compounds that would downregulate PMP22 mRNA overexpression in the human disease situation where disal upstream regulatory elements are present.
Nonetheless, in the quest for a target that may (co)regulate PMP22, we focused on the sexual hormone and neurosteroid progesterone. The progesterone receptor PR is expressed in Schwann cells and the application of progesterone resulted in activation of the Pmp22 gene in vitro 112 and in vivo. 113 We hypothesized that antagonizing the PR may in turn reduce Pmp22 overexpression and therefore could positively influence CMT1A disease. Indeed, therapeutic application of the PR Fig. 1 Therapeutic targets in demyelinating forms of CMT. Genetic defects in myelinating Schwann cells (1) can lead to missorting or accumulation of mutated/overexpressed proteins (2). Besides subsequent demyelination, malfunctioning Schwann cells (3) fail to sustain axonal support (4) which then leads to progressive axonal and neuronal loss (the final common pathway) (5) . The clinical phenotype is ultimately determined by neurogenic muscle atrophy (6) . Different levels of disease have been shown to constitute therapeutic targets for the compounds progesterone antagonist and ascorbic acid, curcumin and neurotrophin-3. Ax, axon; SC, Schwann cell; N, neuron; M, muscle.
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antagonist Onapristone over 7 weeks starting early post-natally ameliorated the neuropathic phenotype in male CMT rats by reducing the toxic overexpression of Pmp22 mRNA, although we cannot rule out neuroprotective features of the drug itself. 33 These results may be translated to CMT1A patients who present disease onset in young adolescence and may therefore expect severe disease progression. 114 Onapristone also prevented the axonal loss in a long-term study using female CMT rats when treatment was started at 4 weeks of age, similar to the age when CMT1A patients present in the clinic in young adolescence. 36 Unexpectedly, Onapristone-treated CMT rats displayed unaltered myelin sheath thickness, thus uncoupling the Schwann-cell functions of myelination and axonal support. 19 Onapristone displayed side effects in humans (e.g. liver-function test abnormalities) and is not available. We are, therefore, currently examining the effect of a new PR antagonist which is safe for humans (B. Weiss and R. Fledrich, unpublished). Our studies with PR antagonists demonstrate that targeting the toxic overexpression of the PMP22 gene is a promising rational to treat CMT1A.
Vitamin C lowers Pmp22 expression and ameliorates the phenotype in a mouse model of CMT Ascorbic acid (Vitamin C) is a naturally occurring organic compound with antioxidant properties required for myelinating Schwann cells to form extracellular matrices and basal laminae in vitro 115 In severely affected PMP22 transgenic mice (C22 het line, see above), the weekly oral application of ascorbic acid reduced PMP22 mRNA overexpression (Fig. 1) , lowered the number of severely hypomyelinated axons, improved the motor performance and increased the life span of mice. 40 It was suggested that ascorbic acid may act on PMP22 by competing with cAMP, a second messenger with the potency to drive Pmp22 expression. 40, 116 Whether the antioxidative properties of ascorbic acid affected the demyelinating phenotye in the C22 het line has not been examined. However, the results from the PMP22 transgenic mouse model and the simple translation of ascorbic acid, an over the counter drug, to patients with CMT1A launched a number of large-scale multicentric trials. 20 -23 Unfortunately, none of the clinical phase-2 trials reported beneficial effects of ascorbic acid to patients with CMT1A thus far. Nonetheless, small effects may have been missed due to insensitivity of the outcome measures in patients with CMT1A (see below). 23 
Neurotrophin 3 causes axonal regeneration in xenograft explants of patients with CMT1A
The loss of peripheral axons ultimately determines the disease severity in patients with CMT1A. 17, 117 Rescue of axonal degeneration as well as supporting their regeneration constitutes a further therapeutic strategy in CMT1A as shown by a reduced axonal loss in WldS/Pmp22 double-transgenic rats 118 ( Fig. 1) . Neurotrophin 3 (NT-3) has been reported to promote nerve regeneration after injury and the survival of Schwann cells. 119 Therapeutic application of NT-3 in immune incompetent mice with xenograft transplants of sural nerve biopsies from patients with CMT1A (as well as from Trembler-J mice) augmented axonal regeneration. 120 Improved regeneration and remyelination, mostly of small calibre axons, was achieved by subcutaneous injection of recombinant NT-3 three times a week. This observation was translated to patients with CMT1A, and a clinical pilot study was performed. 120 In a small group of eight patients with CMT1A NT-3 treatment was well tolerated when performed three times weekly over a 6-month time period. The patients with CMT1A displayed an increase in myelinated fibre density, a reduction in the neurological impairment score as well as improved sensory modalities when compared with placebo controls. 120 However, considering the small number of patients, these results must be confirmed in larger cohort studies.
Macrophages constitute a putative therapeutic target in CMT1A
Experimental studies have demonstrated that macrophages and T lymphocytes are a pathological feature of mice carrying mutations in myelin proteins. 121 -125 Genetic suppression of T-and B-lympocyte functions using RAG-1-deficient mice ameliorated the demyelinating phenotype in GJB1-deficient mice, whereas it worsened disease progression in MPZ-deficient mice. 87, 122 Low copy number Pmp22 transgenic mice (C61 het line) display no pathological amelioration when crossbred with Rag-1 mutants, indicating that lymphocytes are not pathogenetically relevant in this CMT1A model. 126 Ablation of the chemokine monocyte chemoattractant protein-1 (MCP-1/CCL2) as well as of the colony-stimulating factor (CSF-1) in GJB1-deficient mice reduced the macrophage abundance and ameliorated the neuropathological features in the respective double mutants. 88, 127 Thus, MCP-1 and CSF-1 may act as macrophage attractants which, in turn, may aggravate neuropathological processes in GJB1-deficient mice. Increased abundance of macrophages in the endoneurial compartment of peripheral nerve has also been reported in C61 het mice as well as in the CMT rats. 123, 128, 129 Accordingly, crossbreeding of the C61 het line to
Mcp-1 null mutants resulted in a reduced macrophage abundance in peripheral nerves and in a remarkable amelioration of the neuropathic phenotype. 128 Furthermore, a higher activation of the MEK/ERK signalling cascade in the mitogen-activated protein kinase pathway was found in peripheral nerves of C61 mice and its pharmacological inhibition by the compound CI-1040 in vivo (daily i.p. injection of 100 mg/ kg over 21 days) effectively reduced the amount of phosphoryated ERK. 128 Interestingly, a reduced relative Mcp-1 mRNA expression in peripheral nerves of C61 mutants was observed upon MEK/ERK inhibition. MEK/ERK signalling is involved in many facets of cellular regulation, from gene expression to cell death. 130 Whether blocking of this important cellular pathway displays a therapeutic strategy which exerts amelioration of the neuropathic phenotype remains to be elucidated. 128 In vitro approaches targeting the P2X7 purinergic receptor and the heat shock protein 90 HSP90
Apart from the reported in vivo studies, in vitro approaches may also identify new targets for a putative therapeutic intervention (Table 1) . Some reports indicate that perturbation of the intracellular calcium homeostasis may be causally involved in demyelinating processes. 131, 132 PMP22 is known to interact with the C-terminal domain of the P2X7 purinergic receptor, leading to receptor activation, channel opening and influx of extracellular Ca 2þ . 133 CMT rat-derived Schwann cells exhibit abnormal high basal concentrations of intracellular calcium which is caused by the superactivation of the purinergic receptor P2X7. 134 By inhibition of the P2X7 receptor, either pharmacologically or by mRNA silencing, the gained intracellular calcium levels of mutant dorsal root ganglion (DRG) neuron/Schwann cell co-cultures could be restored and myelination was improved. 134 Therefore, influencing the intracellular ion homeostasis to a physiological level may constitute a further therapeutic rational in CMT1A.
Therapeutic targets aimed at restoring missorted proteins (curcumin, caloric restriction, rapamycin, small molecule inhibitors of HSP90)
Under normal conditions, PMP22 protein folding is only moderately effective and 80% of the newly synthesized protein is degraded by the proteasome. 55, 135, 136 In Schwann cells of Trembler-J mice, the protein degrading pathways of the lysosome and proteasome are overloaded and abnormal cytosolic aggregates containing mutant (misfolded) PMP22 and ubiquitin are formed. 55, 137 These aggregates (aggresomes) are found in both Pmp22 mutants carrying point mutations (Tr-J) and high copy number Pmp22 overexpressing mice (C22 line). 55, 59 Autophagy emerged to play an important role in the removal of aggresomes 138 and its induction, either by nutrient deprivation or via pharmacological activation by rapamycin, resulted in aggresome degradation in Schwann cells of Pmp22 mutant and overproducing mice. 139 -141 A further promising therapeutic rational for proteinmisfolding disorders involves the enhancement of chaperone expression. 142 Inhibition of heat shock protein 90 (HSP90) by Geldenamycin effectively enhanced cytosolic chaperone levels and improved myelination, along with the trafficking of PMP22 in DRG explant cultures from C22 het neuropathic mice. 143 Supporting the correct protein folding and turnover of PMP22 may therefore constitute a promising therapeutic strategy upon strong PMP22 overexpression. Unfortunately, dramatic caloric restriction is not suitable for CMT patients. For both drugs, Rapamycin and Geldanamycin derivatives, preclinical therapy studies have not been performed yet.
Aggregates containing mutant PMP22 have also been reported to be located and retained in the ER of Trembler-J mice which induces Schwann cell death via apoptosis. 144 Treatment with the curry spice compound curcumin may facilitate the translocation of misfolded protein from the ER to the plasma membrane, subsequently reducing cytotoxicity. 73,145 -147 Importantly, in Trembler-J mice, oral administration of curcumin not only reduced ER retention and cytotoxicity of mutant PMP22 protein, but also mitigated their neuropathic phenotype in a dose-dependent manner. On the histological level, the axonal size and the myelin sheath thickness were improved upon curcumin diet. 144 Besides its effect of facilitating the release of ER-retained proteins, curcumin may also support the axonal survival via its potential as a neuroprotective agent 148 ( Fig. 1) . Given the low toxicity profile of curcumin, this treatment of CMT1E may be well translatable to affected patients.
Therapeutic targets in MPZ-related neuropathies
Similar to PMP22 mutant protein, ER retention and cytotoxicity were also reduced by curcumin treatment in HeLa cells when transfected with S83del mutant forms of MPZ. 73 Furthermore, in MpzS63del transgenic mice, Schwann cells display a consequential canonical unfolded protein response (UPR), including the expression of the transcription factor C/EBP homologous protein (CHOP), a protein previously reported to induce apoptosis in ER-stressed cells. 149 -152 Importantly, genomic ablation of Chop in MpzS63del mice completely Experimental therapy in axonal CMT type 2
In CMT2, primarily axons are affected without myelin deficits resulting in an unaltered NCV (.38 m/s). CMT2 occurs less frequently (20% of all CMT cases) and the clinical phenotype is similar to CMT1. 9 Up to now, mutations in 15 genes/loci are associated with CMT2. 153 Rodent models for some subtypes of CMT2 were generated, 15 e.g. mice carrying mutations in the microtubule motor protein gene Kif1B, 154 in the neurofilament light-chain gene Nefl, 155 in laminin A/C 156 and in the small heat-shock protein gene Hspb1.
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Transgenic mice have been generated in which the expression of mutant NEFL P222S protein in adult neurons can be repressed by the use of the conditional doxycycline-responsive gene system. 158 These mice recapitulated the key features of CMT type 2E (CMT2E), including aberrant hindlimb posture, motor deficits and loss of muscle innervation. Remarkably, the resembled disease hallmarks could be reversed after 3 months of doxycyclin treatment, indicating that the abolishment or neutralization of mutant NEFL may be a promising target for therapeutic approaches in CMT2E. 158 In a mouse model of human CMT type 2F, the expression of mutant HSPB1 led to a decrease in acetylated a-tubulin abundance and induced severe axonal transport deficits. Prevention of a-tubulin deacetylation by pharmacological inhibition of histone deacetylase 6 corrected the impaired axonal transport and rescued the CMT phenotype of symptomatic mutant Hspb1 mice. 157 These findings demonstrate the first therapeutic advance in an animal model of primarily axonal CMT.
Biomarkers may help to translate the findings from experimental therapy to CMT patients Despite its monogenetic cause, patients with CMT1A display a marked interindividual variability of disease severity. The underlying reason for this variability is largely unknown and epigenetic factors have been discussed. 6 At present, the assessment of the individual disease severity in patients with CMT1A is performed only by clinical and electrophysiological examinations. The CMT neuropathy score (CMTNS) is a nine-item composite scale taking into account sensory and motor symptoms, 159 and it is currently being applied as a primary outcome measure in clinical trials. 160 The CMTNS ranges from 1 (good clinical performance) to 36 (severely affected) and was reported to increase only 0.68 points per year in patients with CMT1A. 159 An even slower progression was reported within a recent therapy trial with ascorbic acid (0.25 points per year). 23 Therefore, insensitive outcome measures may increase the risk of false-negative results and biomarkers could add powerful tools to monitor therapeutic effects in clinical trials. 23, 161 CMT rats recapitulate the striking disease variability observed in patients with CMT1A. In a proof of principle study, we have demonstrated that the expression levels of selected genes in sciatic nerve and skin tissue can be utilized to measure and predict the disease severity in CMT rats. Importantly, we validated these disease severity markers in skin biopsies of 46 patients with CMT1A. 35 In future, these markers will be examined with regard to disease progression within a large pan-European consortium.
Conclusions
Although the final clinical presentation in CMT disease is very similar, the pathological mechanisms in Schwann cells leading to demyelination can differ widely. Therefore, therapeutic strategies should be designed according to the disease mechanism. Ultimately, the amount of axonal loss determines clinical severity and directly targeting the 'final common pathway' may be applicable to different CMT subforms. For CMT1A, lowering toxic overexpression of PMP22 may constitute a treatment rational, and the effect of PR antagonists has been shown using the CMT rat model. Tight control of PMP22 expression is crucial for normal peripheral nerve function as not only overexpression (causing CMT1A), but also a reduced expression (causing HNPP) causes neuropathy. A potential therapy aimed at lowering toxic PMP22 overexpression must be, therefore, carefully titrated to reconstitute non-toxic and avoid too low expression levels.
Other therapeutic strategies, e.g. targeting the overloading of the cellular degradative pathways, have also been shown to effectively ameliorate the CMT phenotype in animal models. Drugs aimed to release ER-retained proteins may be applied in certain forms of CMT caused by PMP22 and MPZ point mutations. Importantly, it seems essential to select the appropriate animal model for experimental therapy. For CMT1A, at least two further mouse models (C61 het and C3) seem good models, next to the CMT rat.
However, to translate experimental therapy to patients with CMT1A in form of clinical trials, the reliable outcome measures are necessary because of the slow progression of the disease. The CMTNS is a reliable but insensitive marker of disease severity and barely sufficient to detect the very slow disease progression within clinical trials that are conducted not more than 1-2 years. Biomarkers may not only serve as a sensitive surrogate marker of clinical severity, but also identify responders to a putative therapy. Transcriptional biomarkers for the assessment and prognosis of the disease severity in CMT rats and affected humans indicate that the identification and development of biomarkers in CMT1A is possible. In the near future, we hope to provide the clinical practice with applicable biomarkers which in turn may accelerate the development of a therapy for CMT1A.
